<DOC>
	<DOCNO>NCT02698657</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics multiple ascend intravenous dos ASP5094 male female subject rheumatoid arthritis ( RA ) methotrexate ( MTX ) .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics ASP5094 Following Multiple Intravenous Doses Subjects With Rheumatoid Arthritis Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Subject body mass index ( BMI ) ≤ 35 kg/m2 , inclusive , must weigh least 50 kg screening . Subject absolute neutrophil count within normal limit screen . The assessment may repeat screen . Subject RA diagnose accord 1987 revised criterion American College Rheumatology ( ACR ) ≥ 6 month prior screen . Subject meet ACR 1991 revise criterion Global Functional Status RA , Class I , II III screen . Subject MUST concomitant MTX : ≥ 3 month prior day 1 , stable dose ( 10 25 mg/week ) ≥ 28 day prior day 1 throughout study . Subject 's medication take treatment RA time screen must meet noted stability requirement remain stable regimen , follow : Nonsteroidal antiinflammatory drug ( NSAIDs ) , selective cyclooxygenase2 ( COX 2 ) inhibitor , oral corticosteroid ( ≤ 10 mg prednisone , equivalent , daily ) low dose opioids ( ≤ 30 mg oral morphine , equivalent , daily ) must stable ≥ 28 day prior screen , Hydroxychloroquine ( Plaquenil® ) sulfasalazine ( e.g. , Azulfidine® ) must start ≥ 2 month , stable ≥ 28 day , prior day 1 . Female subject must either : Of nonchildbearing potential : postmenopausal ( define least 1 year without menses ) prior screen , document surgically sterile Or , childbearing potential , Agree try become pregnant study 60 day final study drug administration ; must negative urine pregnancy test screen day 1 , And , heterosexually active , agree consistently use 2 form highly effective birth control† ( least 1 must barrier method ) start screen throughout study period 60 day final study drug administration . Female subject must agree breastfeed start screen throughout study period , 60 day . Female subject must donate ovum start screen throughout study period , 60 day final study drug administration . Male subject female spouse/partner childbearing potential must use highly effective form contraception consist 2 form birth control† ( 1 must barrier method ) start screen continue throughout study period 60 day final study drug administration . Male subject must donate sperm start screen throughout study period , 60 day final study drug administration Subject agree participate another interventional study participate present study , define signing informed consent form completion last study visit . Subject ongoing clinically significant systemic disease uncompensated heart failure , uncontrolled diabetes mellitus , severe hepatic failure , severe pulmonary disease inflammatory bowel disease . Subject history malignancy past 5 year , except adequatelytreated , nonmelanoma skin cancer adequatelytreated insitu cervical cancer . Subject history severe allergic anaphylactic reaction drug . Subject history consume 14 unit alcoholic beverage per week history alcoholism drug/chemical/ substance abuse within past 6 month prior screen ( Note : 1 unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) . Subject ongoing infection infection require intravenous antibiotic within 1 month prior day 1 . Subject known history positive test human immunodeficiency virus ( HIV ) antibody . Subject past history serious opportunistic infection . Subject positive QuantiFERONTB Gold test within 90 day , screening , complete adequate course antimicrobial therapy per Centers Disease Control local guideline . Subject 's laboratory test result screen prior study drug dose day 1 : Outside normal limit consider investigator clinically significant regard remain perprotocol laboratory test , and/or Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal . Subject receive live liveattenuated vaccine within 30 day prior day 1 . Subject receive following : Oral injectable gold , azathioprine , penicillamine , cyclosporine , tacrolimus tofacitinib ( Xeljanz® ) within 30 day prior day 1 . Anakinra ( Kineret® ) , etanercept ( Enbrel® ) , adalimumab ( Humira® ) , tocilizumab ( Actemra® ) , infliximab ( Remicade® ) , golimumab ( Simponi® ) within 60 day prior day 1 . Leflunomide ( Arava® ) within 60 day prior day 1 , unless subject undergone cholestyramine washout least 30 day prior day 1 . Certolizumab ( Cimzia® ) abatacept ( Orencia® ) within 90 day prior day 1 . Rituximab ( Rituxan® ) antiCD20 antibody , cyclophosphamide within 180 day prior day 1 . Treatment conventional disease modify antirheumatic drug ( DMARDs ) , treatment biologics previously note within 28 day 5 halflives , whichever longer , prior day 1 . Subject participate previous clinical study treatment ASP5094 participate another dose cohort current trial . Subject previously receive experimental agent within 28 day 5 halflives , whichever longer , prior day 1 . Subject significant blood loss , donate 1 unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior day 1 . Subject surgery plan elective surgery ( include oral surgery ) within 1 month prior screen 3 month last study drug administration . Subject wound currently heal . Subject condition , opinion investigator , preclude subject 's participation trial . Subject employee Astellas group vendor involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rheumatoid arthritis ( RA )</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>ASP5094</keyword>
</DOC>